Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 1/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CTSD | P07339 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.67 |
| ▸ | CNR1 | P21554 | 1/20 | 0.67 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.62 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.62 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.62 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.62 |
| ▸ | SPPL2A | Q8TCT8 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3471631 | 1.00 | MLNR (0.67) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL3652143 | 1.00 | MLNR (0.67) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL1094790 | 1.00 | MLNR (0.67) | MLNRABCB11LMNACTSDCYP3A4 | |
| Alcohol SCHEMBL2969860 | 0.97 | MLNR (0.64) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL6525403 | 0.93 | SPPL2A (0.61) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL12020180 | 0.92 | SPPL2A (0.58) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL3309955 | 0.92 | MLNR (0.58) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL15737599 | 0.92 | SPPL2A (0.60) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL9223590 | 0.92 | SPPL2A (0.62) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL4346692 | 0.91 | MLNR (0.60) | MLNRABCB11LMNACTSDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2314591-B2 | Pseudopolymorphic forms of a hiv protease inhibitor | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-02-24 | — | — | EP | claimed |
| EP-1567529-B2 | PSEUDOPOLYMORPHIC FORMS OF A HIV PROTEASE INHIBITOR | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-02-24 | — | — | EP | claimed |
| EP-2767539-B1 | Pseudopolymorphic forms of a HIV protease inhibitor | JANSSEN SCIENCES IRELAND UC (IE) | 2017-07-12 | — | — | EP | claimed |
| EP-1567529-B1 | PSEUDOPOLYMORPHIC FORMS OF A HIV PROTEASE INHIBITOR | JANSSEN R & D IRELAND (IE) | 2014-06-18 | — | — | EP | claimed |
| EP-2314591-B1 | Pseudopolymorphic forms of a hiv protease inhibitor | JANSSEN R & D IRELAND (IE) | 2014-06-18 | — | — | EP | claimed |
| US-8518987-B2 | Pseudopolymorphic forms of a HIV protease inhibitor | JANSSEN R&D IRELAND (IE) | 2013-08-27 | — | — | US | claimed |
| US-20100204316-A1 | PSEUDOPOLYMORPHIC FORMS OF A HIV PROTEASE INHIBITOR | Janssen Sciences Ireland Unlimited Company (IE) | 2010-08-12 | — | — | US | claimed |
| US-12564595-B2 | Prophylactic and therapeutic pharmaceutical agent for HIV infectious diseases characterized by comprising combination of integrase inhibitor and anti-HIV agent | SHIONOGI & CO., LTD. (JP) | 2026-03-03 | — | — | US | disclosed |
| EP-3795572-B1 | DARUNAVIR PROPIONATE SOLVATE | LAURUS LABS LTD (IN) | 2023-11-15 | — | — | EP | disclosed |
| US-20230302024-A1 | DARUNAVIR COMBINATION FORMULATIONS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2023-09-28 | — | — | US | disclosed |
| US-20230248712-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES, INC. | 2023-08-10 | — | — | US | disclosed |
| US-11654150-B2 | Darunavir combination formulations | JANSSEN SCIENCES IRELAND UC (IE) | 2023-05-23 | — | — | US | disclosed |
| US-20230059640-A1 | PROPHYLACTIC AND THERAPEUTIC PHARMACEUTICAL AGENT FOR HIV INFECTIOUS DISEASES CHARACTERIZED BY COMPRISING COMBINATION OF INTEGRASE INHIBITOR AND ANTI-HIV AGENT | SHIONOGI & CO., LTD. (JP) | 2023-02-23 | — | — | US | disclosed |
| US-20070060642-A1 | Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate | JANSSEN SCIENCES IRELAND UC (IE) | 2007-03-15 | — | — | US | disclosed |
| US-20050250845-A1 | Pseudopolymorphic forms of a hiv protease inhibitor | TIBOTEC PARMACEUTICEALS | 2005-11-10 | — | — | US | disclosed |
| CN-1668623-A | Pseudopolymorphic forms of a HIV protease inhibitor | TIBOTEC PHARM LTD (IE) | 2005-09-14 | — | — | CN | disclosed |
| EP-1567529-A2 | PSEUDOPOLYMORPHIC FORMS OF A HIV PROTEASE INHIBITOR | Tibotec Pharmaceuticals Ltd. (IE) | 2005-08-31 | — | — | EP | disclosed |
| US-20040116485-A1 | Broad spectrum 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2004-06-17 | — | — | US | disclosed |
| WO-2003106461-A3 | PSEUDOPOLYMORPHIC FORMS OF A HIV PROTEASE INHIBITOR | TIBOTEC PHARM LTD (IE) | 2004-05-13 | — | — | WO | disclosed |
| WO-2003106461-A2 | PSEUDOPOLYMORPHIC FORMS OF A HIV PROTEASE INHIBITOR | TIBOTEC PHARMACEUTICALS LTD (IE) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204316-A1 | PSEUDOPOLYMORPHIC FORMS OF A HIV PROTEASE INHIBITOR | PRSS1, PRSS3, DNPEP | MLNR 3629/4885ABCB11 2707/4885LMNA 4203/4885 |
| US-12564595-B2 | Prophylactic and therapeutic pharmaceutical agent for HIV infectious diseases characterized by comprising combination of integrase inhibitor and anti-HIV agent | RPL35, RPL7, TYMP | MLNR 2103/4885ABCB11 441/4885LMNA 2728/4885 |
| US-20050250845-A1 | Pseudopolymorphic forms of a hiv protease inhibitor | PRSS1, PRSS3, DNPEP | MLNR 3629/4885ABCB11 2707/4885LMNA 4203/4885 |
| US-20230302024-A1 | DARUNAVIR COMBINATION FORMULATIONS | SAMHD1, DARS1, SRI | MLNR 1866/4885ABCB11 39/4885LMNA 3979/4885 |
| US-20070060642-A1 | Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate | HPD, HTR3C, HAAO | MLNR 2506/4885ABCB11 1831/4885LMNA 3850/4885 |
| US-20230059640-A1 | PROPHYLACTIC AND THERAPEUTIC PHARMACEUTICAL AGENT FOR HIV INFECTIOUS DISEASES CHARACTERIZED BY COMPRISING COMBINATION OF INTEGRASE INHIBITOR AND ANTI-HIV AGENT | NHERF1, INO80C, IMPA1 | MLNR 3735/4885ABCB11 13/4885LMNA 2425/4885 |
| US-11654150-B2 | Darunavir combination formulations | SAMHD1, DARS1, SRI | MLNR 1465/4885ABCB11 60/4885LMNA 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.